Cambridge, UK, 9 January 2025 – Panakeia (“the Company”), a pioneer in AI-enabled multi-omic biomarker profiling, today announces that its Founder and CEO, Pahini Pandya, will be attending and presenting at a number of conferences in January 2025.
Panakeia’s AI-driven software provides comprehensive multi-omic information (DNA, RNA, protein, metabolite changes) directly from routinely used images of tissues and cells in minutes instead of days or weeks, without the need for wet-lab tests. The software enables same-day treatment decision-making in the clinic and fast-tracks drug development for biopharma.
Springboard x Accenture: State of Women's Health Breakfast, San Francisco, CA, USA, 13 January 2025
Springboard Enterprises Healthcare & Technology Accelerator Demo Day Showcase Event, San Francisco, CA, USA, 14 January 2025
In person corporate presentation by Founder and CEO, Pahini Pandya
JPM Healthcare conference 2025: Igniting Investment in the Health of Women, San Francisco, CA, USA, 14 January 2025
ASCO Gastrointestinal Cancers Symposium, San Francisco, CA, USA, 23-25 January 2025
Authors: C. Bass, S. Wolf, F. Ntelemis, A. Geraldes, J. Schmidt, D. Mehrotra, S. Singhal, N.M. Orsi, N. Bennett, E.M. Walsh, M. Hyde, G. Rogerson, M. Cummings, C. Freer, P. Pandya, N. Kumar, S. Arslan
Session Name: Poster Session C: Cancers of the Colon, Rectum, and Anus
Session Date and Time: 1/25/2025, 7:00 AM-7:55 AM PT
Abstract ID: 474230
Abstract number: 44
India visit, India, last week of January/ first week of February
CEO and Founder Pahini Pandya will conduct in person meetings with various industry stakeholders
If you would like to meet with the Panakeia team in any of the above conferences, please get in touch via this contact form on our website.
For more information please contact:
Stella Lempidaki, PhD
Head of Communications
About Panakeia
Panakeia is a pioneer in AI-enabled molecular profiling. The Company’s AI-driven software provides comprehensive multi-omic information (DNA, RNA, protein, metabolite changes) directly from routinely used images of tissues and cells in minutes instead of days or weeks. The software enables same-day treatment decision-making in the clinic and fast-tracks drug development for biopharma without the need for time and resource intensive laboratory tests.
Panakeia’s PANProfiler platform is available as a research use tool for patient screening in clinical trials. The Company’s two clinical products for breast and colon cancers are built using the PANProfiler platform. These products are registered and clinically deployed in the UK with several more products in the pipeline.
Headquartered in Cambridge, UK, Panakeia is focused on improving the speed and accuracy of pathology examinations for all patients.
To learn more about Panakeia’s platform visit: https://www.panakeia.ai/